A Retrospective Observational Study to Determine Baseline Characteristics and Early Prescribing Patterns for Patients Receiving Alirocumab in UK Clinical Practice

• Main Authors: Tim Reynolds (Author), Peter Carey (Author), Jacob George (Author), Gerasimos Konidaris (Author), Deepa Narayanan (Author), Sudarshan Ramachandran (Author), Luke Saunders (Author), Adie Viljoen (Author), Gordon Ferns (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2019-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) and has been previously shown, in the phase III ODYSSEY clinical trial program, to provide significant lowering of low-density lipoprotein cholesterol (LDL-C) and reduction in...